Actuate Therapeutics, Inc. Common stock (ACTU)vsJohnson & Johnson (JNJ)
ACTU
Actuate Therapeutics, Inc. Common stock
$0.38
-4.06%
HEALTHCARE · Cap: $14.53M
JNJ
Johnson & Johnson
$271.17
+0.86%
HEALTHCARE · Cap: $615.87B
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
ACTU
Avoid20
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACTU.
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$271.17
$127.05 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Areas to Watch
Trading at 9.6x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ACTU
ACTU has a balanced fundamental profile.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bear Case : ACTU
The primary concerns for ACTU are Price/Book, Revenue Growth, EPS Growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ACTU profiles as a value stock while JNJ is a mature play — different risk/reward profiles.
ACTU carries more volatility with a beta of 1.20 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 20/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Actuate Therapeutics, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative treatments for serious diseases, particularly in the oncology space. The company is advancing its proprietary drug candidates through comprehensive clinical trials, addressing significant unmet medical needs to enhance patient outcomes. With a focus on building a robust pipeline of transformative therapeutic solutions, Actuate is positioned to drive strategic growth and deliver substantial value to its investors, solidifying its competitive edge within the biotechnology industry.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?